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Abstract
Background—We previously reported an increased risk of all-cause and AIDS mortality among
HIV-infected women with albuminuria (proteinuria or microalbuminuria) enrolled in the Women’s
Interagency HIV Study (WIHS) prior to the introduction of highly active antiretroviral therapy
(HAART).
Methods—The current analysis includes 1,073 WIHS participants who subsequently initiated
HAART. Urinalysis for proteinuria and semi-quantitative testing for microalbuminuria from two
consecutive study visits prior to HAART initiation were categorized as follows: confirmed
proteinuria (both specimens positive for protein), confirmed microalbuminuria (both specimens
positive with at least one microalbuminuria), unconfirmed albuminuria (one specimen positive for
proteinuria or microalbuminuria), or negative (both specimens negative). Time from HAART
initiation to death was modeled using proportional hazards analysis.
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Results—Compared to the reference group of women with two negative specimens, the hazard
ratio (HR) for all-cause mortality was significantly elevated for women with confirmed
microalbuminuria (HR 1.9; 95% CI 1.2–2.9). Confirmed microalbuminuria was also
independently associated with AIDS death (HR 2.3; 95% CI 1.3–4.3), while women with
confirmed proteinuria were at increased risk for non-AIDS death (HR 2.4; 95% CI 1.2–4.6).
Conclusions—In women initiating HAART, pre-existing microalbuminuria independently
predicted increased AIDS mortality, while pre-existing proteinuria predicted increased risk of non-
AIDS death. Urine testing may identify HIV-infected individuals at increased risk for mortality
even after the initiation of HAART. Future studies should consider whether these widely available
tests can identify individuals who would benefit from more aggressive management of HIV
infection and comorbid conditions associated with mortality in this population.
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Microalbuminuria is prevalent among HIV-infected individuals [1] [2] [3] and predicts
mortality in other high-risk populations.[4] We have previously reported that prior to the
introduction of highly active antiretroviral therapy (HAART),[5] HIV-infected women with
proteinuria or microalbuminuria had an increased risk of all-cause and AIDS-related
mortality. The current analysis investigates whether pre-existing microalbuminuria also
predicts mortality among HIV-infected women who initiate HAART.
Methods
The Women’s Interagency HIV Study (WIHS) has been described. [6] HIV-infected and
high-risk seronegative women were enrolled from six United States sites. Social and medical
history, HIV-RNA, CD4, hemoglobin, serum albumin, and urinalysis were ascertained at
enrollment and every six months. Hepatitis serologies and serum creatinine were performed
at enrollment, and creatinine was repeated annually. Glomerular filtration rate (GFR) was
estimated using the 4-variable Modification of Diet in Renal Disease (MDRD) equation.[7]
The institutional review board of each site approved the WIHS protocol, and participants
provided written informed consent.
Urine specimens were collected every 6 months for the first 3 years and stored at −70°C in a
central repository. Specimens were excluded if there was evidence of cystitis, as previously
described. [5] Semi-quantitative microalbuminuria testing (Clinitek Microalbumin Reagent
Strips and Clinitek 50 Analyzer, Siemens Healthcare Diagnostics, Deerfield, IL) was
performed in banked specimens from the first two eligible visits for each participant. Quality
assurance testing was performed using standardized controls (Bio-Rad Laboratories,
Hercules, CA). Microalbuminuria was defined as an albumin: creatinine ratio > 30 mg/g (3.4
mg/mmol). Women with urinalysis protein ≥1+ at both visits were considered to have
“confirmed proteinuria.” Women with microalbuminuria at both visits or with
microalbuminuria at one visit and proteinuria at the other were considered to have
“confirmed microalbuminuria.” Women with proteinuria or microalbuminuria at only one
visit were considered to have “unconfirmed albuminuria.” This analysis excluded women
who initiated HAART prior to the second urine visit. Among included participants, the
median time from the second urine visit to HAART initiation was 728 days.
Data on vital status and date of death were collected from medical records, providers,
personal contacts, and the National Death Index. Cause of death was ascertained from the
death certificate, medical records, providers, or personal contacts, in that order, and
categorized as AIDS or non-AIDS using previously described methods. [8]
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HIV-infected women enrolled in 1994–1995 who subsequently initiated HAART were
included in this analysis. Sustained HAART use was defined as self-reported use for ≥ 3
consecutive visits prior to March 2009. The date of HAART initiation was defined as the
mid-point between the last pre-HAART visit and the first visit at which HAART use was
reported. Women with > 2 missed visits between the last pre-HAART visit and the first
HAART visit were excluded. Continuous and categorical variables were compared by level
of albuminuria using Kruskal-Wallis and chi-square tests, respectively. A 2-sided p-value of
<0.05 was considered significant. Kaplan-Meier and proportional hazards models evaluated
the association of albuminuria with time from HAART initiation to death. Multivariate
models adjusted for demographics and laboratory results at the last pre-HAART visit (age,
race-ethnicity, log transformed HIV-RNA, CD4, hemoglobin, serum albumin, and GFR), as
well as for relevant clinical conditions (hepatitis C co-infection, diabetes, and blood
pressure). Prior AIDS-defining illness (ADI) was ascertained at the first HAART visit, in
order to include events that prompted initiation. When data were missing, the value was
obtained from the most recent prior visit. All analyses were performed using SAS (version
9.1.3; SAS).
Results
A total of 2,059 HIV-infected women were enrolled in WIHS during 1994–1995. Among
the 1,390 participants who subsequently initiated HAART during the study period, 1,073
(77%) were included in this analysis. Women were excluded if they initiated HAART prior
to the second urine visit (n=54), had < 2 eligible urine specimens (n=206), or had > 2 missed
visits between the last pre-HAART visit and the first HAART visit (n=57). Excluded
women were similar with respect to age and race-ethnicity (data not shown).
Among included participants, 107 (10%) had unconfirmed albuminuria, 42 (4%) had
confirmed microalbuminuria, and 33 (3%) had confirmed proteinuria. Albuminuria was
associated with black race, as well as with GFR<60ml/min/1.73m2, higher HIV-RNA,
higher blood pressure, and lower hemoglobin and serum albumin at the last pre-HAART
visit (Table 1).
There were 301 deaths during the study period, including 130 AIDS deaths and 171 non-
AIDS deaths (Table 1). Figure 1 shows the time to all-cause, AIDS, and non-AIDS death
following HAART initiation. Compared to the reference group of women with no
albuminuria, women with confirmed microalbuminuria had the highest risk for all-cause
mortality (HR 3.0; 95% CI 2.0–4.6), followed by those with confirmed proteinuria (HR 2.3;
95% CI 1.4–3.9). Only confirmed microalbuminuria was significantly associated with AIDS
death when considered separately (Figure 1b), while women with either confirmed
microalbuminuria or confirmed proteinuria were at increased risk for non-AIDS death
(Figure 1c). Women with a single episode of albuminuria were at modestly increased risk
for all-cause mortality (HR 1.6; 95% CI 1.1–2.2), but unconfirmed albuminuria was not
statistically associated with AIDS or non-AIDS death.
In multivariate analysis (Table 2), confirmed microalbuminuria remained significantly
associated with all-cause (HR 1.9; 95% CI 1.2–2.9) and AIDS mortality (HR 2.3; 95% CI
1.3–4.3), but the association with non-AIDS death was no longer significant. Only the
association of confirmed proteinuria with non-AIDS death remained significant (HR 2.4;
95% CI 1.2–4.6). In addition to albuminuria, the only other factor that was independently
associated with time to both AIDS and non-AIDS death was GFR<60ml/min/1.73m2.
Results were similar when the CKD-EPI equation [9] was used to estimate GFR (data not
shown). Other factors independently associated with AIDS death included CD4, HIV-RNA,
and hemoglobin prior to HAART initiation (Table 2). Factors associated with non-AIDS
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death included older age, hepatitis C co-infection, current smoking, and lower serum
albumin. Although CD4, HIV-RNA, and time to HAART initiation did not predict non-
AIDS death, history of ADI remained marginally associated with non-AIDS mortality.
Discussion
We have previously demonstrated an increased risk of all-cause and AIDS-related mortality
among HIV-infected women with microalbuminuria prior to the introduction of HAART.
[5] In the current analysis of 1,073 HIV-infected women who subsequently initiated
HAART, pre-existing microalbuminuria was associated with a similar 2-fold increase in the
risk of all-cause and AIDS death. These observations suggest that screening for albuminuria
may identify HIV-infected individuals at increased risk for mortality even after HAART
initiation.
Chronic kidney disease (CKD), as indicated by overt proteinuria or decreased GFR, has
been associated with increased mortality in the general population and in HIV-infected
women. [10][11] [12] [13] In an earlier analysis of WIHS censored in 2002, proteinuria
detected by routine urinalysis was associated with a more than 2-fold increased risk of all-
cause mortality among women who initiated HAART, although deaths were not classified
by relationship to AIDS. [11] More recently, studies in predominantly male populations
have demonstrated associations between overt proteinuria and cardiovascular events in HIV-
infected individuals. [14] [15] While detailed data on cause of death were not available for
the current analysis, cardiovascular disease was a common cause of non-AIDS mortality in
an earlier analysis of WIHS. [16] Future studies should consider whether HIV-infected
individuals with overt proteinuria would benefit from more intensive management of
cardiovascular risk factors and other comorbidities that may contribute to non-AIDS
mortality.
Microalbuminuria has also been associated with mortality and cardiovascular disease in
HIV-negative patient populations. [4] Although microalbuminuria may indicate early CKD,
it has also been hypothesized to reflect systemic inflammation [3] and generalized
endothelial dysfunction. [4] In a prior analysis of 162 WIHS participants with serial
albuminuria measurements, albuminuria stabilized in women who initiated HAART, but
continued to increase in untreated controls. [17] Microalbuminuria was hypothesized to
reflect inflammation and endothelial dysfunction resulting from active viral replication. The
results of the current analysis suggest that pre-existing microalbuminuria may continue to
predict AIDS-related outcomes even after the initiation of HAART.
Future studies are needed to determine whether microalbuminuria predicts mortality in HIV-
infected men or from specific causes. Other important limitations are the possible
underestimation of albuminuria in women taking angiotensin converting enzyme inhibitors
or angiotensin receptor blockers, and the misclassification of women who developed new
albuminuria in the interval between the confirmatory urine test and HAART initiation.
Misclassification may also have occurred due to the limited sensitivity of dipstick assays to
detect lower levels of proteinuria [18] and microalbuminuria, or due to decreased sensitivity
of microalbuminuria testing in banked urine.[19] These types of misclassification, however,
would be expected to bias our results towards the null. Finally, we had limited power to
exclude an association between overt proteinuria and AIDS mortality or to evaluate the
effect of individual ART regimens.
The current study suggests that albuminuria testing before initiation of HAART may
identify individuals at increased risk for mortality despite HAART. Screening for CKD,
including assessment for overt proteinuria, is currently standard of care in HIV-infected
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individuals.[20] Future studies should investigate whether additional microalbuminuria
testing is a cost-effective approach to identify high-risk patients, who may benefit from
more aggressive management of comorbidities and behavioral factors known to contribute to
mortality.
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Figure 1.
Kaplan-Meier estimates of time to all-cause (a), AIDS (b), and non-AIDS death (c).
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Table 1
Characteristics of included WIHS participants prior to the initiation of highly active antiretroviral therapy
(HAART).
No
Albuminuria
n=891 (83.0%)
Unconfirmed
Albuminuria
n=107 (10.0%)
Confirmed
Microalbuminuria
n=42 (3.9%)
Confirmed
Proteinuria
n=33 (3.1%)
Age, years* 39.6 (34.5, 44.7) 42.6 (35.5, 46.5) 43.8 (35.7,49.1) 39.2 (34.0, 42.5)
Race***
  Black (including Hispanic) 465 (52.2%) 78 (72.9%) 34 (81.0%) 27 (81.8%)
  White (including Hispanic) 191 (21.4%) 17 (15.9%) 3 (7.1%) 5 (15.2%)
  Other 235 (26.4%) 12 (11.2%) 5 (11.9%) 1 (3.0%)
CD4 cell count, cells/mm3 280 (149, 430)
[n=890]
231 (122, 406) 209.5 (125, 325) 202 (97, 413)
Log10 HIV-RNA* 4.2 (3.3, 4.8) 4.3 (3.6, 5.0) 4.3 (3.4, 5.1) 4.5 (4.0, 5.2)
Prior AIDS-defining illness 449 (50.4%) 59 (55.1%) 28 (66.7%) 18 (54.6%)
Hepatitis C co-infection* 292 (32.8%) 49 (45.8%) 17 (40.5%) 11 (33.3%)
Hepatitis B co-infection 19 (2.1%) 5 (4.7%) 0 (0%) 2 (6.1%)
Diabetes mellitus 47 (5.3%) 5 (4.7%) 4 (9.5%) 1 (3.0%)
Systolic blood pressure, mmHg** 114 (106, 124) 120 (110, 130) 120 (110, 140) 120 (106, 140)
Diastolic blood pressure, mmHg*** 74 (68, 80) 80 (70, 88) 80 (73, 90) 78 (70, 93)
Smoking history
  Current 454 (51.0%) 66 (61.7%) 22 (52.4%) 19 (57.6%)
  Former 215 (24.1%) 20 (18.7%) 5 (11.9%) 8 (24.2%)
GFR < 60mL/min/1.73m2 *** 45 (5.1%)
[n=890]
11 (10.3%) 13 (31.0%) 14 (42.4%)
Hemoglobin, g/dL*** 12.5 (11.6, 13.4)
[n=890]
12.1 (11.9, 13.2)
[n=106]
11.6 (11.0, 12.2) 11.4 (10.4, 12.7)
Serum albumin, g/dL*** 4.1 (3.9, 4.4)
[n=890]
4.0 (3.8, 4.2) 3.9 (3.4, 4.1) 3.7 (3.3, 4.0)
Outcomes
  Time to HAART initiation, days 735 (512, 1305) 721 (518, 1428) 712 (531, 1088) 560 (498, 792)
  Follow-up on HAART, days 4058 (3207, 4390) 4045 (3408, 4456) 4176 (4011, 4333) 4227 (3280, 4428)
  Loss to follow-up 119 (13.4%) 8 (7.5%) 1 (2.4%) 4 (12.1%)
  Early virologic suppression 630 (72.5%)
[n=869]
69 (65.1%)
[n=106]
29 (78.4%)
[n=37]
26 (81.3%)
[n=32]
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No
Albuminuria
n=891 (83.0%)
Unconfirmed
Albuminuria
n=107 (10.0%)
Confirmed
Microalbuminuria
n=42 (3.9%)
Confirmed
Proteinuria
n=33 (3.1%)
  All-cause death*** 223 (25.0%) 39 (36.5%) 24 (57.1%) 15 (45.5%)
  AIDS death** 98 (11.0%) 17 (15.9%) 12 (28.6%) 3 (9.1%)
  Non-AIDS death*** 125 (14.0%) 22 (20.6%) 12 (28.6%) 12 (36.4%)
Categorical variables are reported as number (%), and continuous variables as median (interquartile range).
*
p-value: <0.05,
**
<0.01 and
***
< 0.001.
Chi-square test for categorical variables and Kruskal-Wallis for continuous variables. Where data are missing, the number of participants with
available data is listed. HAART, highly active antiretroviral therapy; Prior AIDS-defining illness, based on the 1993 Centers for Disease Control
surveillance case definition excluding the CD4 criteria, reported at or before the first visit where HAART use was reported; Hepatitis C co-
infection, hepatitis C antibody positive and RNA positive or unknown at enrollment; Hepatitis B co-infection, hepatitis B surface antigen positive
at enrollment; GFR, estimated glomerular filtration rate; Time to HAART initiation, time from the second urine visit to HAART initiation; Early
virologic suppression, undetectable HIV-RNA at the study visit following the first report of HAART use.
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Table 2
Multivariate proportional hazards models for time to death.
All-Cause Death
Adjusted HR (95% CI)
AIDS Death
Adjusted HR (95% CI)
Non-AIDS Death
Adjusted HR (95% CI)
Albuminuria
  No albuminuria (Reference)
  Unconfirmed albuminuria 1.1 (0.8, 1.6) 1.3 (0.8, 2.2) 1.0 (0.6, 1.6)
  Confirmed microalbuminuria 1.9 (1.2, 2.9)** 2.3 (1.3, 4.3)** 1.7 (0.9, 3.3)
  Confirmed proteinuria 1.6 (0.9, 2.8)* 0.7 (0.2, 2.1) 2.4 (1.2, 4.6)**
GFR < 60mL/min/1.73m2 1.9 (1.3, 2.7)*** 2.1 (1.3, 3.6)** 1.8 (1.2, 2.9)**
Age (per 10 years) 1.0 (1.0, 1.1)*** --- 1.1 (1.0, 1.1)***
CD4 (per 100 cells/mm3) 0.9 (0.8, 0.9)*** 0.7 (0.6, 0.8)*** ---
Log10 HIV RNA 1.2 (1.1, 1.4)*** 1.4 (1.2, 1.7)*** ---
Prior AIDS-defining illness 1.3 (1.0, 1.7)* --- 1.5 (1.1, 2.0) *
Hepatitis C co-infection 1.4 (1.1, 1.8)* --- 1.7 (1.2, 2.3)**
Smoking history
  Current 1.7 (1.2, 2.3)** 1.3 (0.9, 1.9) 2.8 (1.7, 4.9)***
  Former 0.9 (0.6, 1.4) 0.7 (0.4, 1.1) 1.7 (0.9, 3.0)
Hemoglobin, g/dL (per unit increase) 0.9 (0.8, 1.0)** 0.8 (0.7, 0.9)*** ---
Serum albumin, g/dL (per unit increase) 0.7 (0.5, 0.9)** --- 0.6 (0.4, 0.8)***
*
p-value: 0.05,
**
<0.01 and
***
<0.001 by Wald Test.
Hepatitis C co-infection, hepatitis C antibody positive and RNA positive or unknown; GFR, estimated glomerular filtration rate. Race, hepatitis B
status, diabetes, blood pressure, and time to HAART initiation were not retained in the final multivariate models, which were based on stepwise
selection with a p-value < 0.05 for retention.
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